系统评价和荟萃分析:中药汤剂可治疗白塞病

2021-10-12 August MedSci原创

白塞病(BD)是一种系统性血管炎的自身免疫性疾病,发病机制尚不清楚。尽管西药仍然是主要的干预措施,但有效性和安全性是重大挑战。补充和替代医学,包括草药,越来越受到关注。

白塞氏病 (BD),也称为白塞氏综合征,是一种累及多个系统的慢性炎症性血管炎。它的典型特征是复发性口腔溃疡、生殖器溃疡、眼部病变和皮肤病变。大多数报道平均发病年龄为20~30岁,男性发病率高于女性。虽然病因尚不清楚,但它被认为是一种自身免疫性疾病,具有遗传易感性和感染相关触发因素,由免疫细胞、趋化因子和细胞因子介导。T 细胞,尤其是 Th1 和 Th17 的稳态扰动,现在被认为是 BD 发病机制的主要免疫学基础。

对于治疗,通常使用皮质类固醇、免疫调节剂、免疫抑制剂和肿瘤坏死因子 (TNF) α 抑制剂。治疗的主要目标是防止炎症的影响,并抑制疾病进展达到靶器官损伤的程度。然而,西医治疗的长期弊端包括副作用、耐药性、停药后复发等。例如,由于致畸性,沙利度胺禁用于孕妇。因此,对于某些 BD 患者群体,治疗选择是有限的。

补充和替代医学,包括草药,越来越受到关注。据报道,草药可以降低疾病风险并提高人体免疫力,因此它们在癌症患者的免疫调节中发挥积极作用。也有证据表明,草药中的某些成分可作为抗炎剂,模拟类黄酮、类固醇、生物碱、糖苷、多酚、姜黄素、萜类化合物、γ-亚麻酸、酚类二萜和 harpagoside与合成类固醇和非甾体抗炎药相比,它们的副作用更少,成本更低。

在中医理论中,白塞病在临床表现和病机上与护火病相似。护火的出现,最早见于《金室纲要》。在这重要参考文献中,论述了甘草泻心汤、赤小豆当归散等经典治疗方剂。经过数千年的实际应用和调整,发展出更多的经典方剂,也值得进一步关注。此综述的目的是评估中药汤剂治疗 BD 的有效性和安全性。

其方法是在 6 个电子数据库中检索了截至 2021 年 3 月的中药汤剂治疗 BD 的随机对照试验 (RCT)。主要结果是总有效率、康复率和复发率。次要结果是临床特征评分(口腔溃疡、眼部病变、生殖器溃疡、皮肤病变、关节病、发热和病理反应)和实验室指标水平(红细胞沉降率、C 反应蛋白和免疫球蛋白 A)。使用 Cochrane 手册评估偏倚风险,并使用 RevMan 5.4.1 进行荟萃分析。

得到结果:该评价纳入了 16 项随机对照试验,共 924 名患者。荟萃分析表明,与对照组相比,中药汤剂对 BD 的所有主要结局和次要结局的有效率为 7/10。16 项随机对照试验中有 11 项报告了不良事件,中药汤剂的不良事件可能少于西药。该评论包括一系列经典处方。对加味甘草泻心汤治疗 BD 进行了额外的荟萃分析。甘草泻心汤作为代表性方剂也被讨论,以及高频草药,值得进一步探索个体化医学和药理学。

荟萃分析表明,与对照组相比,中药汤剂的总有效率和治愈率显着更高,复发率显着降低,然而,证据不足以支持中药汤剂可有效降低发热、CRP 和 IgA 水平。安全性方面,在其他八项报告不良事件的研究中,实验组的不良事件发生率低于对照组,这表明中药汤剂的不良事件发生率可能低于西药。总之,中药汤剂作为治疗BD的补充和替代疗法是有价值的。中药汤剂有可能有效且安全地治疗 BD。而由于纳入研究的质量不令人满意,还需要额外的精心设计的 RCT 来证实这些发现。

原文:Yan J, Yan Y, Young A, Yan Z, Yan Z. Effectiveness and Safety of Chinese Medicine Decoctions for Behcet's Disease: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2021;2021:8202512. Published 2021 Jul 17. doi:10.1155/2021/8202512

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836987, encodeId=aa9a183698e0f, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Thu Feb 24 11:22:26 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214617, encodeId=5c31121461ea8, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:04 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681428, encodeId=b8d4168142852, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Aug 02 03:22:26 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070744, encodeId=32d410e0744c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56095714142, createdName=ms5000000753978789, createdTime=Tue Nov 16 12:41:21 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444724, encodeId=2eb01444e2480, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Oct 14 00:22:26 CST 2021, time=2021-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836987, encodeId=aa9a183698e0f, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Thu Feb 24 11:22:26 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214617, encodeId=5c31121461ea8, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:04 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681428, encodeId=b8d4168142852, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Aug 02 03:22:26 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070744, encodeId=32d410e0744c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56095714142, createdName=ms5000000753978789, createdTime=Tue Nov 16 12:41:21 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444724, encodeId=2eb01444e2480, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Oct 14 00:22:26 CST 2021, time=2021-10-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1836987, encodeId=aa9a183698e0f, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Thu Feb 24 11:22:26 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214617, encodeId=5c31121461ea8, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:04 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681428, encodeId=b8d4168142852, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Aug 02 03:22:26 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070744, encodeId=32d410e0744c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56095714142, createdName=ms5000000753978789, createdTime=Tue Nov 16 12:41:21 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444724, encodeId=2eb01444e2480, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Oct 14 00:22:26 CST 2021, time=2021-10-14, status=1, ipAttribution=)]
    2022-08-02 venlin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1836987, encodeId=aa9a183698e0f, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Thu Feb 24 11:22:26 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214617, encodeId=5c31121461ea8, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:04 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681428, encodeId=b8d4168142852, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Aug 02 03:22:26 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070744, encodeId=32d410e0744c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56095714142, createdName=ms5000000753978789, createdTime=Tue Nov 16 12:41:21 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444724, encodeId=2eb01444e2480, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Oct 14 00:22:26 CST 2021, time=2021-10-14, status=1, ipAttribution=)]
    2021-11-16 ms5000000753978789

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1836987, encodeId=aa9a183698e0f, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Thu Feb 24 11:22:26 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214617, encodeId=5c31121461ea8, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:04 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681428, encodeId=b8d4168142852, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Aug 02 03:22:26 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070744, encodeId=32d410e0744c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56095714142, createdName=ms5000000753978789, createdTime=Tue Nov 16 12:41:21 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444724, encodeId=2eb01444e2480, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Oct 14 00:22:26 CST 2021, time=2021-10-14, status=1, ipAttribution=)]
    2021-10-14 huagfeg

相关资讯

J Cosmet Dermatol:中药调理霜可有效调理黄褐斑

黄褐斑是一种后天性的、常见的面部色素沉着症。虽然目前治疗方法很多,但疗效一般。为了研究一种含有中草药混合物的膏药治疗黄褐斑的安全性和有效性。

Clin Trans Gastroenterology:中草药治疗儿童便秘的效果分析

便秘是儿童时期最常见的胃肠道不适,估计影响了全球约20%的儿童,儿童便秘的治疗策略包括饮食控制,行为干预和口服泻药等。

中草药治疗抑郁症具有一定的潜力

神经免疫系统和神经内分泌系统是抑郁症发病机制中的两个关键生物系统。多药多靶点中草药(CHM)在协助开发用于抑郁症系统药物治疗的新型药物方面具有巨大潜力。

Ann Otol Rhinol Laryngol:简单急性细菌鼻窦炎的草药EPs 7630与阿莫西林治疗比较

之前的调查表明了天竺葵根提取物(EPs 7630)可用于对简单急性上呼吸道炎症的治疗,由于其有很强的抗细菌和免疫调节作用。最近,有研究人员比较了EPs 7630与阿莫西林单独治疗在治疗轻度到中度急性细

Biomed Chromatogr:知柏草煎剂口服后八种生物活性成分的药代动力学研究及临床疗效观察

知桥草(ZQGC)煎剂因其对腰椎间盘突出症(LDH)的治疗作用而在国内得到广泛应用。本研究采用视觉模拟量表、Oswestry伤残指数、MacNab评分比较了口服ZQGC煎剂治疗、卧床休息和口服消炎药塞

梳理那些可以治疗癫痫的中药

中草药治疗癫痫的历史悠久。由于西方抗癫痫治疗的副作用以及对更容易获得的治疗的追求,补充和替代药物变得流行。一些中草药已被证明具有抗癫痫作用,不同草药的联合使用通过各种机制发挥抗惊厥作用。